Ahmed Serkan Emekli

Adjunct Postgraduate Fellow






European Academy of Neurology, Examination of European Board of Neurology, 3rd prize, 2022.
Turkish Neurological Society, National Neurology Board Examination, 1st price, 2019.
Eskisehir Neuro-Rheumatology Days, Best Oral Presentation Award Winner, 2021. “Analysis of Lesion Localization Pattern of Patients with Parenchymal Neuro-Behçet’s Disease Using Probability Mapping”.
Selected Publications: 
Emekli AS, Doğan FU, Gündüz T, Sezgin M, Ekizoğlu E, Yeşilot N, Çoban O, Akman G, Kürtüncü M. Lesion probability map in cerebral vein thrombosis due to Behçet's disease. Int J Rheum Dis. 2022 Oct 9. Online ahead of print.
Emekli AS, Ersozlu E, Emekli MA, Gunduz T, Kurtuncu M. Lesion Distribution Pattern of Parenchymal Neuro-Behçet's Disease Using Probability Mapping. Mult Scler Relat Disord. Article in press. 2021.
Emekli AS, Hanagasi HA. Dopamine Agonist-Associated Hiccup in Parkinson’s Disease: A Case Report. Arch Neuropsychiatry 2021;58:253−254.
Emekli AS, Parlak A, Göcen NY, Kürtüncü M. Anti-GAD associated post-infectious cerebellitis after COVID-19 infection. Neurol Sci. 2021 Jul 30:1–8. doi: 10.1007/s10072-021-05506-6
Emekli AS, Samanci B, Şimşir G, Hanagasi HA, Gürvit H, Bilgiç B, Başak AN. A novel PNPLA6 mutation in a Turkish family with intractable Holmes tremor and spastic ataxia. Neurol Sci. 2021;42:1535-1539
Samancı B, Şahin E, Şen C, Samancı Y, Sezgin M, Emekli S, Kocasoy Orhan E, Orhan KS, Baykan B. Olfactory dysfunction in patients with cluster headache. Eur Arch Otorhinolaryngol. 2021 Mar 13.
Sub-investigator - Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) - NCT02239120
Sub-investigator - An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment - NCT02861014
Sub-investigator - Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis - NCT03085810
Sub-investigator - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension - NCT03179631
Resident Location
Current Resident Location: 
Selected Presentations: 
Emekli A, Ersozlu E, Gunduz T, Kurtuncu M. Analysis of Lesion Localization Pattern of Patients with Parenchymal Neuro-Behçet’s Disease Using Probability Mapping. Neurology Apr 2020, 94 (15 Supplement) 2717. American Academy of Neurology Congress 2020.
A.S. Emekli, E. Ersozlu, M. Kurtuncu, T. Gunduz, M. Eraksoy. Is Placebo Effect Getting Bigger In Randomized Controlled Trials of Multiple Sclerosis?. 34th Congress of ECTRIMS.

Contact Info.

MSU Clinical Center
804 Service Road
Room: A-217
East Lansing
Office Phone: 517-353-8122
Clinic Phone: 517-353-8122

Developed by DECS | Contact Information | Privacy Statement | Site Accessibility

MSU is an affirmative action, equal opportunity employer

© Michigan State University Board of Trustees, East Lansing, MI 48824